search

Active clinical trials for "Neoplasms, Second Primary"

Results 11-20 of 267

Laser Interstitial Thermal Ablation and Stereotactic Radiosurgery for Patients With Spine Metastases...

Neoplasm MetastasisSpinal Cord Diseases3 more

The purpose of this research is to combine two complementary modes of treatment, spinal interstitial laser ablation and stereotactic spine radiosurgery (SSRS) for the treatment for spinal tumors near the spinal cord with an objective to improve tumor control, improve pain control, preserve function, and improve quality of life. We will also assess how effective these combined modes of treatment are in patients with spinal metastasis with an epidural component.

Recruiting20 enrollment criteria

Effect of Azeliragon Combined With Stereotactic Radiation Therapy in Patients With Brain Metastases...

CancerMetastasis4 more

To determine the safety and efficacy of using the drug azeliragon combined with stereotactic radiosurgery. Specifically, to determine if this combination will lead to improved response in the brain (tumor shrinking in size) and overall tumor control (how long tumor remains controlled).

Recruiting22 enrollment criteria

Actinium 225 Labeled Anti-CEA Antibody (Ac225-DOTA-M5A) for the Treatment of CEA Producing Advanced...

Advanced CancerMetastatic Cancer

This phase I study tests the safety, side effects, and best dose of Ac225-DOTA-M5A in treating patients with CEA positive colorectal cancer that has spread to other places in the body (advanced). Ac225-DOTA-M5A is a humanized monoclonal anti-CEA antibody, linked to a radioactive agent called actinium 225. M5A attaches to CEA positive cancer cells in a targeted way and delivers actinium 225 to kill them.

Recruiting19 enrollment criteria

First-in-Human Study of TAK-280 in Participants With Unresectable Locally Advanced or Metastatic...

Unresectable Locally Advanced or Metastatic Cancer

The main aim of this study is to find out the safety, tolerability, and effect of TAK- 280 in participants with unresectable, locally advanced or metastatic cancer who have experienced treatment failure or are intolerant to standard therapies. Participants will be treated with TAK-280 for up to 14 treatment cycles. Each treatment cycle will be 28 days. After the last dose of study drug, participants will be followed up for survival every 12 weeks for a total of 48 weeks.

Recruiting14 enrollment criteria

Study of TY-9591 in Patients With a Lung Cancer With Brain or Leptomeningeal Metastases With EGFR...

NSCLCEGFR Activating Mutation2 more

To evaluate the efficacy and safety of TY-9591 tablets in the treatment of EGFR mutation-positive non-small cell lung cancer (NSCLC) patients with brain or leptomeningeal metastases.

Recruiting43 enrollment criteria

Surgery With Extended (D3) Mesenterectomy for Small Bowel Tumors

Small Bowel CancerSmall Bowel Carcinoid Tumor3 more

The study is designed to investigate the safety and efficacy of central D3 lymphadenectomy in cases of small bowel tumors. Such dissection is under debate; consensus guidelines are vague when it comes to surgical techniques and practice is highly variable.

Recruiting6 enrollment criteria

The Safety and Efficacy of Redsenol-1 Plus on Cancer-related Fatigue in Adults Who Have Received...

FatigueCancer1 more

The primary objective of this study is to evaluate the safety and efficacy of Redsenol-1 Plus on cancer-related fatigue (CRF) in adults who have received cancer treatment. The change in the severity of CRF from baseline at week 12 will be assessed by the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) fatigue subscale, and compared between Redsenol-1 Plus and placebo groups. Additionally, the safety and tolerability of Redsenol-1 Plus, as compared to placebo, will be measured by the occurrence of and/or changes in treatment-emergent adverse events (AEs).

Recruiting34 enrollment criteria

E6201 and Dabrafenib for the Treatment of Central Nervous System Metastases From BRAF V600 Mutated...

Clinical Stage IV Cutaneous Melanoma AJCC v8Metastatic Malignant Neoplasm in the Brain2 more

This phase I tests the safety, side effects, and best dose of E6201 in combination with dabrafenib in treating patients with BRAF V600 mutated melanoma that has spread to the central nervous system (central nervous system metastases). E6201 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Dabrafenib is used in patients whose cancer has a mutated (changed) form of a gene called BRAF. It is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals tumor cells to multiply. This helps stop the spread of tumor cells. Giving E6201 and dabrafenib together may work better in treating patients with BRAF V600 mutated melanoma that has spread to the central nervous system than either drug alone.

Recruiting48 enrollment criteria

A Study of Stereotactic Radiosurgery (SRS) for People With Lung Cancer That Has Spread to the Brain...

Lung CancerLung Cancer Metastatic5 more

The purpose of the study is to see if stereotactic radiosurgery/SRS is an effective treatment for people with a new diagnosis of brain metastases from small cell lung cancer/SCLC.

Recruiting11 enrollment criteria

Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing...

SarcomaSynovial9 more

A Phase I/II Dose Escalation, Safety and Efficacy Study of HBI 0201-ESO TCRT (anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes) Given by Infusion to Patients with NY-ESO-1 -Expressing Metastatic Cancers

Recruiting41 enrollment criteria
123...27

Need Help? Contact our team!


We'll reach out to this number within 24 hrs